» Articles » PMID: 28246524

Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma

Overview
Journal Sarcoma
Publisher Wiley
Date 2017 Mar 2
PMID 28246524
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

. Ezrin is a membrane-cytoskeleton linker protein that has been associated with metastasis and poor outcomes in osteosarcoma and high-grade soft tissue sarcomas. The prognostic value of ezrin expression in Ewing sarcoma is unknown. . The relationship between ezrin expression and outcome was analyzed in a cohort of 53 newly diagnosed Ewing sarcoma patients treated between 2000 and 2011. The intensity and proportion of cells with ezrin immunoreactivity were assessed in diagnostic tumor tissue using a semiquantitative scoring system to yield intensity and positivity scores for each tumor. . Ezrin expression was detected in 72% (38/53) of tumor samples. The proportion of patients with metastatic disease was equal in the positive and negative ezrin expression groups. There was no significant difference in the 5-year event-free survival (EFS) between patients with positive versus negative ezrin expression. Patients whose tumor sample showed high ezrin intensity had significantly better 5-year EFS when compared to patients with low/no ezrin intensity (78% versus 55%; = 0.03). . Ezrin expression can be detected in the majority of Ewing sarcoma tumor samples. Intense ezrin expression may be correlated with a favorable outcome; however further investigation with a larger cohort is needed to validate this finding.

Citing Articles

CD99 Modulates the Proteomic Landscape of Ewing Sarcoma Cells and Related Extracellular Vesicles.

De Feo A, Manfredi M, Mancarella C, Maqueda J, De Giorgis V, Pignochino Y Int J Mol Sci. 2024; 25(3).

PMID: 38338867 PMC: 10855178. DOI: 10.3390/ijms25031588.


Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A Review.

Song Y, Ma X, Zhang M, Wang M, Wang G, Ye Y Front Cell Dev Biol. 2020; 8:588801.

PMID: 33240887 PMC: 7683424. DOI: 10.3389/fcell.2020.588801.


The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta-analysis.

Wang F, Yu T, Ma C, Zhang H, Zhang Z FEBS Open Bio. 2019; 9(10):1744-1755.

PMID: 31376222 PMC: 6768105. DOI: 10.1002/2211-5463.12713.

References
1.
Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P . Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatr Blood Cancer. 2007; 50(4):752-6. DOI: 10.1002/pbc.21360. View

2.
Yu Y, Khan J, Khanna C, Helman L, Meltzer P, Merlino G . Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004; 10(2):175-81. DOI: 10.1038/nm966. View

3.
Arpin M, Algrain M, Louvard D . Membrane-actin microfilament connections: an increasing diversity of players related to band 4.1. Curr Opin Cell Biol. 1994; 6(1):136-41. DOI: 10.1016/0955-0674(94)90127-9. View

4.
Parlato S, Giammarioli A, Logozzi M, Lozupone F, Matarrese P, Luciani F . CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 2000; 19(19):5123-34. PMC: 302100. DOI: 10.1093/emboj/19.19.5123. View

5.
Soule E, Newton Jr W, MOON T, Tefft M . Extraskeletal Ewing's sarcoma: a preliminary review of 26 cases encountered in the Intergroup Rhabdomyosarcoma Study. Cancer. 1978; 42(1):259-64. DOI: 10.1002/1097-0142(197807)42:1<259::aid-cncr2820420140>3.0.co;2-r. View